Compare EXG & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXG | TWST |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2006 | 2018 |
| Metric | EXG | TWST |
|---|---|---|
| Price | $9.58 | $67.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.88 |
| AVG Volume (30 Days) | 439.7K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | N/A | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $8.25 | $23.30 |
| 52 Week High | $9.78 | $69.20 |
| Indicator | EXG | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 66.47 |
| Support Level | $9.46 | $41.85 |
| Resistance Level | $9.74 | N/A |
| Average True Range (ATR) | 0.12 | 4.26 |
| MACD | 0.01 | 1.45 |
| Stochastic Oscillator | 82.65 | 85.46 |
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.